Latest Content

A first-in-vivo PET study finds M1 receptor availability reduced 13% to 19% across brain regions in schizophrenia, strengthening the case for muscarinic-targeted treatment.

New data show post‑TBI inflammation boosts amyloid; blocking soluble TNF with XPro1595 preserves memory and reduces pain, hinting prevention.

DSM's real weakness isn't categories—it's weak science. Explore when disorders are diseases vs dimensions, and why overlap misleads.

Psychiatrists push to normalize sexual health talks, address medication-related sexual side effects, and reduce stigma with holistic care and patient-safe communication.

Brain capital drives competitiveness—see how ROI-focused mental health care and responsible AI expand access, build resilience, and boost productivity.

PMN310 shows strong 6‑month safety in early Alzheimer disease, with zero ARIA‑E and encouraging tau biomarker shifts before 2027 data.

Northwestern researchers identify a reduced CSF protein signal in schizophrenia and show a synthetic version restores brain circuit activity in mice.

Why teens use drugs and alcohol: avoidant attachment and emotional isolation fuel addiction; attachment-based therapy rebuilds bonds and cuts relapse.

Clinical AI in psychiatry falters when designers miss ward realities; better ethnographic UX research reduces alert fatigue, cognitive load, and boosts meaningful adoption.

Phase 2 ZEPHYR finds oral betovumeline combo reduces PANSS and improves cognition in acute schizophrenia, with generally mild side effects.

After TBI, soluble TNF sparks Alzheimer-like damage; XPro1595 blocks it in mice, preserving memory and reducing pain—hinting prevention.

Concussion recovery in teen athletes often masks anxiety or depression; learn warning signs, screening tips, and safer return-to-play steps.

FDA clears Simtriyo, a first-in-class NDSRI and central nervous system stimulant for ADHD, offering new symptom and executive-function gains.